AZD6750 for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called AZD6750 for individuals with advanced or metastatic solid tumors, which are cancers that have spread and resist standard treatments. The primary goal is to determine if AZD6750 is safe and effective, either alone or with another drug, rilvegostomig. Participants should have specific types of solid tumors, such as certain skin or lung cancers, and must have previously tried other treatments. Those with ongoing serious health issues or specific past treatments might not qualify. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on chronic immunosuppressive therapy or steroids over 10 mg of prednisone per day, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that AZD6750 is being tested for safety in patients with advanced or spreading solid tumors. Earlier studies found AZD6750 alone to be tolerable, with side effects closely monitored. This ensures the treatment's safety for patients.
When combined with rilvegostomig, other studies have shown rilvegostomig to be effective in fighting tumors. However, safety remains a key focus. The combination aims to enhance treatment effects, with researchers closely monitoring any side effects.
Both treatments are still under study. These ongoing trials are crucial to determine how well patients tolerate these treatments and what side effects might occur. This information is vital for anyone considering joining the study.12345Why are researchers excited about this trial's treatments?
Unlike the standard treatments for advanced cancer, which often rely on chemotherapy or targeted therapies, AZD6750 is unique because it introduces a novel mechanism of action. AZD6750, when used alone, is administered intravenously to directly target cancer cells. In combination with rilvegostomig, it potentially enhances the immune response against the tumor, offering a dual approach that both attacks the cancer and bolsters the body's own defenses. Researchers are excited about these treatments because they represent a promising shift towards more personalized and potentially more effective cancer therapies.
What evidence suggests that this trial's treatments could be effective for advanced cancer?
Research has shown that AZD6750 is being tested for its potential to treat advanced or spreading solid tumors. Early results suggest the drug might slow tumor growth and help manage the disease. In this trial, some participants will receive AZD6750 alone, while others will receive it with another drug, rilvegostomig. When combined with rilvegostomig, AZD6750 has shown promise in enhancing treatment effects for certain cancers. Rilvegostomig has already produced positive results in other cancer types, which is encouraging for its use here as well. Although these treatments remain in the early stages, researchers are closely monitoring their potential impact on cancer therapy.12346
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced or metastatic solid tumors, including various types of cancer such as breast, lung, melanoma, squamous cell carcinoma, and others. Specific eligibility criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive AZD6750 as a single agent or in combination with other anti-cancer agents to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
Dose Expansion
Participants receive AZD6750 in combination with other anti-cancer agents to assess preliminary anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD6750
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology